These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 34201650)

  • 1. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
    Chiu LC; Lin SM; Lo YL; Kuo SC; Yang CT; Hsu PC
    Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34201650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
    Li F; Chen Y; Wu J; Li C; Chen S; Zhu Z; Qin W; Liu M; Hu B; Liu S; Zhong W
    Chronic Dis Transl Med; 2022 Jun; 8(2):100-111. PubMed ID: 35774424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
    Riano I; Abuali I; Sharma A; Durant J; Dragnev KH
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Lee JM; Tsuboi M; Brunelli A
    Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer.
    Wang F; Xia T; Li Z; Gao X; Fang X
    Front Oncol; 2023; 13():1213297. PubMed ID: 37727216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.
    Huynh C; Walsh LA; Spicer JD
    Transl Lung Cancer Res; 2021 Jan; 10(1):563-580. PubMed ID: 33569337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
    Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
    Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
    Kang J; Zhang C; Zhong WZ
    Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review.
    Gatteschi L; Iannopollo M; Gonfiotti A
    Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers.
    Wu X; Chau YF; Bai H; Zhuang X; Wang J; Duan J
    Front Oncol; 2022; 12():1099304. PubMed ID: 36761426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
    Isaacs J; Stinchcombe TE
    Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
    Puri S; Shafique M; Gray JE
    Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.